Medicare and Medicaid would test lower prices for many drugs by comparing them with prices in other wealthy countries. The test would run for 5 years starting in 2029. Drug makers would face new price reporting rules and could sign special agreements tied to more U.S. manufacturing.
Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Most Favored Patient Act of 2026 is a House bill committee Action. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Latest action on H.R. 7837: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who this affects: This bill mainly affects people who get covered drugs through Medicaid, Medicare Part D drug plans, or Medicare Part B. It could change what those programs pay and what some patients pay out of pocket. It also affects drug makers that sell covered drugs, because they would face new price reporting rules and pressure to offer lower prices. Federal health officials would have to run the 5-year test, calculate prices, review agreements, and report to Congress.
Why this matters: This bill matters because it could lower what Medicare and Medicaid pay for some costly drugs, which could also lower some patients’ out-of-pocket costs. The exact savings are not clear from the bill. The plan could also change how drug makers set prices, share data, and decide where to make drugs. Because this is a 5-year test, its results could shape future drug pricing policy.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Officially: Most Favored Patient Act of 2026
Medicare and Medicaid would test lower prices for many drugs by comparing them with prices in other wealthy countries. The test would run for 5 years starting in 2029. Drug makers would face new price reporting rules and could sign special agreements tied to more U.S. manufacturing.
Use this page to support, oppose, or ask Congress to amend HR7837. Modern Action explains what the bill does, helps identify the right senators or representative, and drafts a bill-specific message you can edit and send.
Where it stands
Sitting in Energy and Commerce
No vote scheduled. Constituent contact is what moves bills out of committee.
↓ Why your message matters here
This bill is sitting in committee with no scheduled vote — which means a small number of constituent messages can decide whether it moves forward or quietly dies.
Enter your ZIP to see how your senators and member of Congress have voted, sponsored, or spoken on this bill.
Where this bill is in the process
Introduced
Introduced in House
House Committee
Under House committee consideration
Latest: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (3/5/2026)
House Floor Vote
Voted on by House
Passed House
Approved by House
Senate Review
Sent to Senate for consideration
Passed Both Chambers
Approved by both House and Senate
Signed into Law
Signed by the President
For more detail
Choose one clear position: support, oppose, or amend. Then pick any reasons or personal context you want included. Modern Action uses that input and the bill context to draft a message you can edit and send.
Congressional offices prioritize messages from their own constituents. Modern Action uses your address to route the drafted message to your House representative when that is the most relevant target for this bill.
The draft includes the bill number, your position, the reasons you selected, any personal context you added, and a direct ask such as voting yes, voting no, cosponsoring, opposing, or seeking changes. You stay in control because you can edit the message before sending.
This page gives you an opportunity to support, oppose, or ask for changes to Most Favored Patient Act of 2026, then contact the elected officials who can act. Modern Action drafts the message from your position and the reasons you select.
Modern Action keeps the action tied to the bill itself: what it does, where it is in the process (Committee Action), which office can still act, and what ask belongs in the message.
You are not starting from a blank form. Modern Action drafts the message around HR7837, your stance, and the reasons you choose, then lets you edit and send when ready.
